Michelle Robertson, EVP, CFO and Treasurer of Geron, will present a case study on how to prepare a company for the transition from a clinical development to a commercial organization based on her experiences launching a first-of-its-kind medicine.
In June 2024, Geron received FDA approval for RYTELO™ (imetelstat), the first-ever telomerase inhibitor, for the treatment of certain adults with lower-risk MDS with transfusion-dependent anemia, following a multi-decade scientific and drug development journey to bring the potential of telomerase inhibition to patients. Key takeaways will include how and where to invest your resources; mitigating risks as a company doubles in size; and making strategic investments to set your company up for success.
- Best practices to maximize capital use and minimize waste across development phases and launch.
- Flexible and robust budgeting techniques that adapt to unexpected changes and regulatory shifts in development.
- Long-term financial strategies that align with business goals and maintain investor confidence.
